A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT02713867
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — BIOLOGICAL
Study Details
The primary objective of this study is to compare PFS (progression-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks with nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).
Key Dates
- First listed
- Mar 21, 2016
- Start date
- May 24, 2016
- Status verified
- Jan 2023
- Primary completion
- Jul 15, 2019
- Completion
- Jan 18, 2022
Study Design
- Enrollment
- 363 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Nivolumab 240 mgNivolumab 240 mg Every 2 Weeks
- Experimental: Nivolumab 480 mgNivolumab 480 mg Every 4 Weeks
Primary Outcome Measure
Progression Free Survival Rate (PFSR) at 6 Months [ Time Frame: At 6 Months ]
Locations (77)
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Detection of Genetic Markers of Lung CancerRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Lung Cancer Biomarkers and ScreeningRecruiting · NYU Langone Health · New York, New York